Bausch Health Companies (DB:BVF) - Hisse Senedi Fiyatı, Haberler ve Analizler

BVF Stoklara Genel Bakış

Bausch Health Companies Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda çeşitlendirilmiş bir özel ilaç ve tıbbi cihaz şirketi olarak faaliyet göstermektedir. Daha fazla detay

BVF temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 84.5% daha düşük bir oranda işlem görüyor

Kazançların yılda 218.28% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 34.6% oranında arttı

Risk Analizi

Negatif hissedar öz sermayesi

Bausch Health Companies Inc. Rakipler

Dermapharm Holding

XTRA:DMP

€2.0b

Bayer

XTRA:BAYN

€18.8b

PharmaSGP Holding

XTRA:PSG

€304.6m

Merck KGaA

XTRA:MRK

€61.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bausch Health Companies
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$8.66
52 Haftanın En Yüksek Seviyesi	US$9.82
52 Haftanın En Düşük Seviyesi	US$4.69
Beta	0.74
11 Aylık Değişim	17.12%
3 Aylık Değişim	68.01%
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-58.46%
5 Yıllık Değişim	-66.49%
Halka arzdan bu yana değişim	-4.21%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	BVF	DE Pharmaceuticals	DE Pazar
7D	0%	1.6%	1.1%
1Y	n/a	-19.0%	7.2%

Getiri vs. Endüstri: BVF un German Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: BVF un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is BVF's price volatile compared to industry and market?
BVF volatility
BVF Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: Veri mevcut değil.

Zaman İçindeki Volatilite: BVF 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda çeşitlendirilmiş bir özel ilaç ve tıbbi cihaz şirketi olarak faaliyet göstermektedir. Başta gastroenteroloji, hepatoloji, nöroloji, dermatoloji, uluslararası ilaçlar, reçetesiz (OTC) ürünler, estetik tıbbi cihazlar ve göz sağlığı alanlarında bir dizi ürün geliştirmekte, üretmekte ve pazarlamaktadır. Şirket beş segmentte faaliyet göstermektedir: Salix, International, Solta Medical, Diversified ve Bausch + Lomb.

Bausch Health Companies Inc. Temel Bilgiler Özeti

Bausch Health Companies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BVF temel i̇stati̇sti̇kler
Piyasa değeri	€2.83b
Kazançlar(TTM)	-€168.48m
Gelir(TTM)	€8.97b

0.3x

P/S Oranı

-16.8x

F/K Oranı

BVF aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BVF gelir tablosu (TTM)
Gelir	US$9.47b
Gelir Maliyeti	US$2.76b
Brüt Kâr	US$6.71b
Diğer Giderler	US$6.89b
Kazançlar	-US$178.00m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.48
Brüt Marj	70.87%
Net Kâr Marjı	-1.88%
Borç/Özkaynak Oranı	-8,887.2%

BVF uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BVF Stoklara Genel Bakış

Ödüller

Risk Analizi

Bausch Health Companies Inc. Rakipler

XTRA:DMP

€2.0b

XTRA:BAYN

€18.8b

XTRA:PSG

€304.6m

XTRA:MRK

€61.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Second quarter 2024 earnings released: EPS: US$0.027 (vs US$0.071 in 2Q 2023)

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.55 loss in 1Q 2023)

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

No longer forecast to breakeven

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold €708k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Investor sentiment improved over the past week

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit